Evaluation of Fisetin to Reduce Systemic Senescence
Evaluation of Fisetin to Reduce Systemic Senescence Indices: A Randomized Controlled Dosing Equivalence Study
This is a prospective, randomized clinical trial to evaluate the ability of the supplement, Fisetin, to safely reduce systemic senescence (aging) indices assessed in peripheral blood.
연구 개요
상태
상태
정황
정황
개입 / 치료
개입 / 치료
상세 설명
This is a prospective, randomized clinical trial designed to examine the effect of two different Fisetin dosing schedules on peripheral blood cells and biomarkers related to aging as well as the occurrence of side effects. The purpose of this study is to evaluate the ability of the supplement, Fisetin, to safely reduce systemic senescence (aging) indices assessed in peripheral blood. 96 healthy volunteers will be randomized into one of two arms (1:1). Group 1 - n= 48: Fisetin Daily Dosing; Group 2 - n=48: Fisetin Bolus Dosing.
연구 유형
연구 유형
등록 (실제)
등록
단계
단계
- 2 단계
- 1단계
연락처 및 위치
연구 장소
-
-
Colorado
-
Vail, Colorado, 미국, 81657
- Steadman Philippon Research Institute
-
-
참여기준
자격 기준
자격 기준
공부할 수 있는 나이
건강한 자원 봉사자를 받아들입니다
연구 대상 성별
설명
Inclusion Criteria:
- Adults ≥55 years of age;
- Capacity to personally give informed consent (consent via legally authorized representative will not be accepted);
- Willing to comply with all study procedures and assessments.
Exclusion Criteria:
-
Within 2 years of signing informed consent history of active blood disorders (i.e., DVTs, chronic blood clotting, hemophilia, leukemia, myeloma, etc.); or active malignancy of any type or history of a malignancy (with the exception of Subjects with a history of treated basal or squamous cell carcinoma);
-
Females who are nursing a child, are pregnant, or are planning to become pregnant during drug dosing;
-
Males who do not wish to abstain from sex with women of childbearing potential without use of contraceptive protection by either party during drug dosing;
-
Any significant illness within the last 30 days requiring clinical care, and/or any medications, medical condition, including findings in medical history or in the baseline assessments that, in the opinion of the Principal Clinical Investigator or the screening clinician, constitutes a risk or contraindication for participation in the study or that could interfere with the study conduct, endpoint evaluation, or prevent the subject from fully participating in all aspects of the study;
-
Allergy to any active or inactive ingredient of Fisetin, and/or taking medication with known Fisetin interaction;
-
Subjects with any of the following drug/medication statuses:
- Taking medications that affect insulin activity, including Metformin or Acarbose, within one week of signing informed consent;
- Currently taking Warfarin or related anticoagulants;
- Currently taking Lithium;
- Senolytic agents taken within the past 3 months and are not willing to discontinue these medications through the duration of the study, including: Fisetin, Quercetin, Luteolin, Dasatinib, Piperlongumine, or Navitoclax;
- Taking drugs that induce significant cellular stress and are not willing to discontinue these medications through the duration of the study, including alkylating agents, anthracyclines, platins, and other chemotherapy drugs;
- Taking the following drugs if they cannot be held (per the Principal Investigator) for at least 2 days before and during administration of Fisetin: cyclosporine, tacrolimus, repaglinide, and bosentan;
- Taking a glucocorticoid within 1 month of signing informed consent;
- Currently taking phenytoin or nateglinide;
-
PHQ-9 - Patient Health Questionnaire - total score exceeds 9;
-
Inability to tolerate oral medication;
공부 계획
연구는 어떻게 설계됩니까?
디자인 세부사항
- 주 목적: 치료
- 할당: 무작위
- 중재 모델: 병렬 할당
- 마스킹: 없음(오픈 라벨)
팔의 수
무기와 개입
참가자 그룹 / 팔참가자 그룹 / 팔 |
개입 / 치료개입 / 치료 |
|---|---|
|
실험적: Fisetin (daily dosing)
A single Fisetin 100mg capsule will be taken daily for 60 days. |
Oral Fisetin 100mg capsule
다른 이름들:
|
|
실험적: Fisetin (bolus dosing)
Fisetin 100 mg capsules (~20 mg/ kg/ day) will be administered orally for two consecutive days (days 1 and 2) followed by 28 days off. This cycle of 2 dosing days followed by 28 days off will repeat for a total of 2 cycles, or 4 dosing days total. Dosing days will occur on days 1&2, and 31&32. |
Oral Fisetin 100mg capsule, dosed at 20 mg/kg
다른 이름들:
|
연구는 무엇을 측정합니까?
주요 결과 측정
주요 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
Change from baseline in levels of senescent PBMCs (total and specific PBMC subsets such as T-Cells)
기간: Baseline, Visit 4 (45 days)
|
Cell types measured via flow cytometry and analyzed via immunophenotype and senescent panels. |
Baseline, Visit 4 (45 days)
|
2차 결과 측정
2차 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
Change from baseline in levels of senescent PBMCs (total and specific PBMC subsets such as T-Cells)
기간: Baseline, Visit 2 (15 days), Visit 3 (35 days), Visit 5 (60 days)
|
Cell types measured via flow cytometry and analyzed via immunophenotype and senescent panels. |
Baseline, Visit 2 (15 days), Visit 3 (35 days), Visit 5 (60 days)
|
|
Change from baseline in senescence-related serum biomarkers
기간: Baseline, Visit 2 (15 days), Visit 3 (35 days), Visit 4 (45 days), Visit 5 (60 days)
|
Concentrations of proteins related to senescence will be analyzed using multiplex immunoassays and ELISA from serum/plasma. |
Baseline, Visit 2 (15 days), Visit 3 (35 days), Visit 4 (45 days), Visit 5 (60 days)
|
|
Number of participants experiencing one or more treatment-emergent adverse events
기간: From date of study drug dosing until the end of the study, an average of 2 months
|
Number of participants experiencing one or more treatment-emergent adverse events |
From date of study drug dosing until the end of the study, an average of 2 months
|
|
Perturbations in senescent PBMC values
기간: Baseline, Visit 2 (15 days), Visit 3 (35 days), Visit 4 (45 days), Visit 5 (60 days)
|
Cell types measured via flow cytometry and analyzed via immunophenotype and senescent panels. |
Baseline, Visit 2 (15 days), Visit 3 (35 days), Visit 4 (45 days), Visit 5 (60 days)
|
|
Perturbations in senescent serum/plasma biomarkers values
기간: Baseline, Visit 2 (15 days), Visit 3 (35 days), Visit 4 (45 days), Visit 5 (60 days)
|
The variability over visits of serum/plasma concentrations of proteins related to senescence will be assessed using multiplex immunoassay and ELISA. |
Baseline, Visit 2 (15 days), Visit 3 (35 days), Visit 4 (45 days), Visit 5 (60 days)
|
공동 작업자 및 조사자
수사관
수사관
- 수석 연구원: Johnny Huard, PhD, Steadman Philippon Research Institute
연구 기록 날짜
연구 주요 날짜
연구 시작 (실제)
연구 시작
기본 완료 (실제)
기본 완료
연구 완료 (실제)
연구 완료
연구 등록 날짜
최초 제출
최초 제출
QC 기준을 충족하는 최초 제출
QC 기준을 충족하는 최초 제출
처음 게시됨 (실제)
처음 게시됨
연구 기록 업데이트
마지막 업데이트 게시됨 (실제)
마지막 업데이트 게시됨
QC 기준을 충족하는 마지막 업데이트 제출
QC 기준을 충족하는 마지막 업데이트 제출
마지막으로 확인됨
마지막으로 확인됨
추가 정보
이 연구와 관련된 용어
키워드
추가 관련 MeSH 약관
기타 연구 ID 번호
기타 연구 ID 번호
- 2022-154
개별 참가자 데이터(IPD) 계획
개별 참가자 데이터(IPD)를 공유할 계획입니까?
약물 및 장치 정보, 연구 문서
미국 FDA 규제 의약품 연구
미국 FDA 규제 기기 제품 연구
이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .